MYCN and neuroblastoma: To examine the therapeutic potential of I-BET726 in vivo, we established subcutaneous xenograft models of non-MYCN-amplified and MYCN-amplified neuroblastoma in immunocompromised mice using the SK–N-AS and CHP-212 cell lines, respectively.